ALK and non-small cell lung carcinoma: Several years ago, crizotinib was established as the standard first-line therapy for advanced ALK-positive NSCLC, because it was demonstrated to be superior to standard chemotherapy (both progression-free survival and objective response rates) in patients with ALK-positive NSCLC [127,128,129,130].